{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:03:23Z","timestamp":1792206203103,"version":"4.4.0"},"reference-count":349,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017639","name":"Entasis Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017639","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Paratek"},{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zavante"},{"name":"Sempra"},{"DOI":"10.13039\/100013993","name":"Theravance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013993","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016956","name":"Melinta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Veterans Health Administration"},{"name":"VenatoRx"},{"name":"Allecra"},{"DOI":"10.13039\/501100015512","name":"Wockhardt","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015512","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Harrington Foundation"},{"name":"Tetraphase and Steris"},{"name":"Antimicrobial Agents and Chemotherapy"},{"name":"mBio"},{"name":"Veterans Affairs Society for Prevention of Infectious Diseases"},{"name":"Qpex Biopharma"},{"name":"Accelerate Diagnostics"},{"name":"CDC"},{"DOI":"10.13039\/100001062","name":"Wallace H. Coulter Endowment","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001062","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Rempex and Antimicrobial Resistance Services"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000313","name":"British Society for Antimicrobial Chemotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017624","name":"Achaogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JAC-Antimicrobial Resistance"},{"DOI":"10.13039\/501100001704","name":"European Society of Clinical Microbiology and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001704","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Astellas"},{"DOI":"10.13039\/100010643","name":"Cidara","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010643","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scynexis"},{"name":"Needham & Associates"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Infectious Diseases Society of America (IDSA) is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. The initial guidance document on infections caused by extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa) was published on 17 September 2020. Over the past year, there have been a number of important publications furthering our understanding of the management of ESBL-E, CRE, and DTR-P. aeruginosa infections, prompting a rereview of the literature and this updated guidance document.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections reviewed, updated, and expanded previously developed questions and recommendations about the treatment of ESBL-E, CRE, and DTR-P. aeruginosa infections. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Preferred and alternative treatment recommendations are provided with accompanying rationales, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, duration of therapy, and other management considerations are also discussed briefly. Recommendations apply for both adult and pediatric populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The field of antimicrobial resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial-resistant infections. This document is current as of 24 October 2021. The most current versions of IDSA documents, including dates of publication, are available at www.idsociety.org\/practice-guideline\/amr-guidance\/.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciac268","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T07:18:09Z","timestamp":1649920689000},"page":"187-212","source":"Crossref","is-referenced-by-count":519,"title":["Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum \u03b2-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and\n                    <i>Pseudomonas aeruginosa<\/i>\n                    with Difficult-to-Treat Resistance (DTR-\n                    <i>P. aeruginosa<\/i>\n                    )"],"prefix":"10.1093","volume":"75","author":[{"given":"Pranita D","family":"Tamma","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel L","family":"Aitken","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Michigan Health , Ann Arbor, Michigan , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Bonomo","sequence":"additional","affiliation":[{"name":"Medical Service and Center for Antimicrobial Resistance and Epidemiology, Louis Stokes Cleveland Veterans Affairs Medical Center, University Hospitals Cleveland Medical Center and Departments of Medicine, Pharmacology, Molecular Biology, and Microbiology, Case Western Reserve University , Cleveland, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J","family":"Mathers","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Pathology, University of Virginia , Charlottesville, Virginia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"van Duin","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina School of Medicine , Chapel Hill, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius J","family":"Clancy","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"2023020110333832100_ciac268-B1","doi-asserted-by":"crossref","DOI":"10.15620\/cdc:82532","volume-title":"Antibiotic resistance threats in the United States 2019","author":"Centers for Disease Control and Prevention","year":"2019"},{"key":"2023020110333832100_ciac268-B2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciz1040","article-title":"Charting the path forward: development, goals and initiatives of the 2019 infectious diseases Society of America strategic plan","volume":"69","author":"Sears","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B3","first-page":"1803","article-title":"Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B4","doi-asserted-by":"crossref","first-page":"e103\u2013","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B5","doi-asserted-by":"crossref","first-page":"ofab434","DOI":"10.1093\/ofid\/ofab434","article-title":"Optimizing the management of uncomplicated gram-negative bloodstream infections: consensus guidance using a modified Delphi process","volume":"8","author":"Heil","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023020110333832100_ciac268-B6","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1914433","article-title":"Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012\u20132017","volume":"382","author":"Jernigan","year":"2020","journal-title":"N Engl J Med"},{"key":"2023020110333832100_ciac268-B7","doi-asserted-by":"crossref","first-page":"ofz353","DOI":"10.1093\/ofid\/ofz353","article-title":"Molecular epidemiology of ceftriaxone non-susceptible enterobacterales isolates in an academic medical center in the United States","volume":"6","author":"Tamma","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2023020110333832100_ciac268-B8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B9","doi-asserted-by":"crossref","first-page":"e00127-21","DOI":"10.1128\/JCM.00127-21","article-title":"Prevalence of blaCTX-M genes in gram-negative bloodstream isolates across 66 hospitals in the United States","volume":"59","author":"Tamma","year":"2021","journal-title":"J Clin Microbiol"},{"key":"2023020110333832100_ciac268-B10","doi-asserted-by":"crossref","first-page":"e00047-19","DOI":"10.1128\/CMR.00047-19","article-title":"Epidemiology of \u03b2-lactamase-producing pathogens","volume":"33","author":"Bush","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"2023020110333832100_ciac268-B11","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of \u03b2-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B12","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1128\/AAC.01896-13","article-title":"Contemporary diversity of \u03b2-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent beta-lactamase groups","volume":"58","author":"Castanheira","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B13","doi-asserted-by":"crossref","first-page":"dlab092","DOI":"10.1093\/jacamr\/dlab092","article-title":"Extended-spectrum \u03b2-lactamases: an update on their characteristics, epidemiology and detection","volume":"3","author":"Castanheira","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2023020110333832100_ciac268-B14","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1128\/JCM.01687-08","article-title":"Unreliable extended-spectrum \u03b2-lactamase detection in the presence of plasmid-mediated AmpC in Escherichia coli clinical isolates","volume":"47","author":"Robberts","year":"2009","journal-title":"J Clin Microbiol"},{"key":"2023020110333832100_ciac268-B15","volume-title":"M100: performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2021","edition":"31st ed."},{"key":"2023020110333832100_ciac268-B16","doi-asserted-by":"crossref","first-page":"dlab019","DOI":"10.1093\/jacamr\/dlab019","article-title":"PRO: testing for ESBL production is necessary for ceftriaxone-non-susceptible Enterobacterales: perfect should not be the enemy of progress","volume":"3","author":"Tamma","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2023020110333832100_ciac268-B17","doi-asserted-by":"crossref","first-page":"dlab020","DOI":"10.1093\/jacamr\/dlab020","article-title":"CON: testing for ESBL production is unnecessary for ceftriaxone-resistant Enterobacterales","volume":"3","author":"Mathers","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2023020110333832100_ciac268-B18","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jama.2018.3627","article-title":"Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial","volume":"319","author":"Huttner","year":"2018","journal-title":"JAMA"},{"key":"2023020110333832100_ciac268-B19","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1001\/archinte.167.20.2207","article-title":"Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women","volume":"167","author":"Gupta","year":"2007","journal-title":"Arch Intern Med"},{"key":"2023020110333832100_ciac268-B20","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/jama.293.8.949","article-title":"Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial","volume":"293","author":"Hooton","year":"2005","journal-title":"JAMA"},{"key":"2023020110333832100_ciac268-B21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/jama.2012.80","article-title":"Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial","volume":"307","author":"Hooton","year":"2012","journal-title":"JAMA"},{"key":"2023020110333832100_ciac268-B22","doi-asserted-by":"crossref","first-page":"a816","DOI":"10.1136\/bmj.a816","article-title":"FDA adds","volume":"337","author":"Tanne","year":"2008","journal-title":"BMJ"},{"key":"2023020110333832100_ciac268-B23","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.02176-12","article-title":"Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection","volume":"57","author":"Brown","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/cid\/ciz169","article-title":"Association between antibiotic use and hospital-onset clostridioides difficile infection in US acute care hospitals, 2006\u20132012: an ecologic analysis","volume":"70","author":"Kazakova","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B25","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/496986","article-title":"Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec","volume":"41","author":"Pepin","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"Extended-spectrum beta-lactamases-red espanola de investigacion en patologia infecciosa\/Grupo de Estudio de Infeccion Hospitalaria G. \u03b2-Lactam\/\u03b2-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts","volume":"54","author":"Rodr\u00edguez-Ba\u00f1o","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B27","first-page":"e13792","article-title":"Oral amoxicillin-clavulanic acid treatment in urinary tract infections caused by extended-spectrum beta-lactamase-producing organisms","volume":"8","author":"Beytur","year":"2015","journal-title":"Jundishapur J Microbiol"},{"key":"2023020110333832100_ciac268-B28","doi-asserted-by":"crossref","first-page":"e02165-18","DOI":"10.1128\/AAC.02165-18","article-title":"A systematic review of single-dose aminoglycoside therapy for urinary tract infection: is it time to resurrect an old strategy?","volume":"63","author":"Goodlet","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B29","doi-asserted-by":"crossref","first-page":"e00749-17","DOI":"10.1128\/mBio.00749-17","article-title":"Widespread fosfomycin resistance in gram-negative bacteria attributable to the chromosomal fosA gene","volume":"8","author":"Ito","year":"2017","journal-title":"mBio"},{"key":"2023020110333832100_ciac268-B30","doi-asserted-by":"crossref","first-page":"e00634-19","DOI":"10.1128\/JCM.00634-19","article-title":"The role of fosA in challenges with fosfomycin susceptibility testing of multispecies Klebsiella pneumoniae carbapenemase-producing clinical isolates","volume":"57","author":"Elliott","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2023020110333832100_ciac268-B31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000220613","article-title":"A clinical trial of alpha-6-deoxyoxytetracycline (doxycycline) in the treatment of urinary tract infections","volume":"14","author":"Mukerji","year":"1969","journal-title":"Chemotherapy"},{"key":"2023020110333832100_ciac268-B32","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1093\/infdis\/131.Supplement.S40","article-title":"Effectiveness of achievable urinary concentrations of tetracyclines against","volume":"131","author":"Musher","year":"1975","journal-title":"J Infect Dis"},{"key":"2023020110333832100_ciac268-B33","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jac\/dkl224","article-title":"Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines","volume":"58","author":"Agwuh","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B34","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"2023020110333832100_ciac268-B35","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0140-6736(12)60608-4","article-title":"Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial","volume":"380","author":"Sandberg","year":"2012","journal-title":"Lancet"},{"key":"2023020110333832100_ciac268-B36","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11255-017-1507-0","article-title":"Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750\u2005mg\/day) or conventional intravenous\/oral levofloxacin (500\u2005mg\/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial","volume":"49","author":"Ren","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"2023020110333832100_ciac268-B37","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","article-title":"Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial","volume":"283","author":"Talan","year":"2000","journal-title":"JAMA"},{"key":"2023020110333832100_ciac268-B38","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1093\/jac\/dkaa369","article-title":"Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis","volume":"75","author":"Elbaz","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B39","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMoa1801467","article-title":"Once-daily plazomicin for complicated urinary tract infections","volume":"380","author":"Wagenlehner","year":"2019","journal-title":"N Engl J Med"},{"key":"2023020110333832100_ciac268-B40","volume-title":"MACROBID - nitrofurantoin monohydrate and nitrofurantoin, macrocrystalline capsule [Package Insert]","author":"Procter and Gamble Pharmaceuticals, Inc"},{"key":"2023020110333832100_ciac268-B41","volume-title":"MONUROL (fosfomycin tromethamine) SACHET [Package Insert]","author":"U.S. Food and Drug Administration"},{"key":"2023020110333832100_ciac268-B42","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/jac\/dkz015","article-title":"Oral fosfomycin for the treatment of chronic bacterial prostatitis","volume":"74","author":"Karaiskos","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B43","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/cid\/civ436","article-title":"Fosfomycin for treatment of prostatitis: new tricks for old dogs","volume":"61","author":"Grayson","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B44","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1093\/cid\/cit704","article-title":"Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis?","volume":"58","author":"Gardiner","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B45","doi-asserted-by":"crossref","first-page":"e3842","DOI":"10.1093\/cid\/ciaa1479","article-title":"Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin\/tazobactam or meropenem from the MERINO study","volume":"73","author":"Henderson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B46","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jamainternmed.2018.6226","article-title":"Association of 30-day mortality with oral step-down vs continued intravenous therapy in patients hospitalized with Enterobacteriaceae bacteremia","volume":"179","author":"Tamma","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2023020110333832100_ciac268-B47","doi-asserted-by":"crossref","first-page":"ofz364","DOI":"10.1093\/ofid\/ofz364","article-title":"Oral fluoroquinolone or trimethoprim-sulfamethoxazole vs. beta-lactams as step-down therapy for Enterobacteriaceae bacteremia: systematic review and meta-analysis","volume":"6","author":"Punjabi","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2023020110333832100_ciac268-B48","volume-title":"AUGMENTIN\u00ae (amoxicillin\/clavulanate potassium): Powder for Oral Suspension and Chewable Tablets [Package Insert]","author":"GlaxoSmithKline"},{"key":"2023020110333832100_ciac268-B49","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1089\/mdr.2019.0423","article-title":"Activity of omadacycline and other tetracyclines against contemporary gram-negative pathogens from New York city hospitals","volume":"27","author":"Iregui","year":"2021","journal-title":"Microb Drug Resist"},{"key":"2023020110333832100_ciac268-B50","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/jac\/dkaa508","article-title":"In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii","volume":"76","author":"Noel","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B51","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1128\/AAC.37.4.851","article-title":"Kinetic interactions of tazobactam with beta-lactamases from all major structural classes","volume":"37","author":"Bush","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B52","volume-title":"PipEracillin tazobactam versus mERoPENem for treatment of bloodstream infections caused by cephalosporin-resistant Enterobacteriaceae (PETERPEN)","author":"Bitterman"},{"key":"2023020110333832100_ciac268-B53","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1093\/cid\/ciz1205","article-title":"Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by extended\u2013spectrum \u03b2\u2013lactamase-producing organisms?","volume":"71","author":"Sharara","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B54","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3906\/sag-1506-157","article-title":"Treatment efficacy and superinfection rates in complicated urinary tract infections treated with ertapenem or piperacillin tazobactam","volume":"46","author":"Dizbay","year":"2016","journal-title":"Turk J Med Sci"},{"key":"2023020110333832100_ciac268-B55","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ijantimicag.2016.12.017","article-title":"Role of piperacillin\/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli","volume":"49","author":"Yoon","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2023020110333832100_ciac268-B56","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12879-017-2502-x","article-title":"Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli","volume":"17","author":"Seo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2023020110333832100_ciac268-B57","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1128\/AAC.00365-16","article-title":"A multinational, preregistered cohort study of \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"60","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B58","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13756-015-0055-6","article-title":"Comparable outcomes for \u03b2-lactam\/\u03b2-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae","volume":"4","author":"Harris","year":"2015","journal-title":"Antimicrob Resist Infect Control"},{"key":"2023020110333832100_ciac268-B59","doi-asserted-by":"crossref","first-page":"e0153696","DOI":"10.1371\/journal.pone.0153696","article-title":"Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"11","author":"Ng","year":"2016","journal-title":"PLoS One"},{"key":"2023020110333832100_ciac268-B60","first-page":"1319","article-title":"Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum \u03b2-lactamase bacteremia","volume":"60","author":"Tamma","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B61","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.diagmicrobio.2014.07.006","article-title":"Carbapenems and piperacillin\/tazobactam for the treatment of bacteremia caused by extended-spectrum \u03b2-lactamase-producing Proteus mirabilis","volume":"80","author":"Tsai","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B62","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1186\/s13104-019-4648-7","article-title":"Risk factors for mortality of patients with ceftriaxone resistant E. coli bacteremia receiving carbapenem versus beta lactam\/beta lactamase inhibitor therapy","volume":"12","author":"Nasir","year":"2019","journal-title":"BMC Res Notes"},{"key":"2023020110333832100_ciac268-B63","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13756-019-0599-y","article-title":"Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia: a retrospective study from 2013 to 2016","volume":"8","author":"Xiao","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"2023020110333832100_ciac268-B64","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10096-017-3133-2","article-title":"Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study","volume":"37","author":"Ko","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B65","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejim.2017.10.014","article-title":"Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in an Italian Internal Medicine ward","volume":"48","author":"Meini","year":"2018","journal-title":"Eur J Intern Med"},{"key":"2023020110333832100_ciac268-B66","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1017\/ice.2015.101","article-title":"Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"36","author":"Ofer-Friedman","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2023020110333832100_ciac268-B67","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/cid\/cix034","article-title":"The use of noncarbapenem beta-lactams for the treatment of extended-spectrum beta-lactamase infections","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B68","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/jac\/dks088","article-title":"Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?","volume":"67","author":"Livermore","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B69","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.2147\/IDR.S166790","article-title":"Comparison of five commonly used automated susceptibility testing methods for accuracy in the China Antimicrobial Resistance Surveillance System (CARSS) hospitals","volume":"11","author":"Zhou","year":"2018","journal-title":"Infect Drug Resist"},{"key":"2023020110333832100_ciac268-B70","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/QCO.0000000000000623","article-title":"Current evidence for therapy of ceftriaxone-resistant gram-negative bacteremia","volume":"33","author":"Paterson","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"2023020110333832100_ciac268-B71","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jac\/dky453","article-title":"OXA-1 \u03b2-lactamase and non-susceptibility to penicillin\/\u03b2-lactamase inhibitor combinations among ESBL-producing Escherichia coli","volume":"74","author":"Livermore","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B72","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1128\/JCM.02128-16","article-title":"Improved accuracy of cefepime susceptibility testing for extended-spectrum-beta-lactamase-producing Enterobacteriaceae with an on-demand digital dispensing method","volume":"55","author":"Smith","year":"2017","journal-title":"J Clin Microbiol"},{"key":"2023020110333832100_ciac268-B73","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijantimicag.2017.09.013","article-title":"Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"51","author":"Kim","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2023020110333832100_ciac268-B74","doi-asserted-by":"crossref","first-page":"ofw132","DOI":"10.1093\/ofid\/ofw132","article-title":"Cefepime therapy for cefepime-susceptible extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae bacteremia","volume":"3","author":"Wang","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2023020110333832100_ciac268-B75","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/cid\/cis916","article-title":"Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters","volume":"56","author":"Lee","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B76","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1128\/AAC.05419-11","article-title":"Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-\u03b2-lactamase-producing Klebsiella pneumoniae and Escherichia coli","volume":"56","author":"Chopra","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B77","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1128\/AAC.47.11.3442-3447.2003","article-title":"Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study","volume":"47","author":"Zanetti","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B78","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.medmal.2014.09.004","article-title":"Clinical spectrum of urine cultures positive for ESBL-producing Escherichia coli in hospitalized patients and impact on antibiotic use","volume":"44","author":"Lepeule","year":"2014","journal-title":"Med Mal Infect"},{"key":"2023020110333832100_ciac268-B79","doi-asserted-by":"crossref","first-page":"e0022621","DOI":"10.1128\/Spectrum.00226-21","article-title":"In vitro activity of Cefotetan against ESBL-producing Escherichia coli and Klebsiella pneumoniae bloodstream isolates from the MERINO Trial","volume":"9","author":"Stewart","year":"2021","journal-title":"Microbiol Spectr"},{"key":"2023020110333832100_ciac268-B80","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/jac\/dkl381","article-title":"Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates","volume":"58","author":"Lee","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B81","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/1471-2334-12-206","article-title":"Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis","volume":"12","author":"Yang","year":"2012","journal-title":"BMC Infect Dis"},{"key":"2023020110333832100_ciac268-B82","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.ijid.2012.09.010","article-title":"The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"17","author":"Doi","year":"2013","journal-title":"Int J Infect Dis"},{"key":"2023020110333832100_ciac268-B83","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s10096-014-2094-y","article-title":"Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae","volume":"33","author":"Pilmis","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B84","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1128\/AAC.00701-15","article-title":"Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-\u03b2-lactamase-producing Escherichia coli bacteremia","volume":"59","author":"Matsumura","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B85","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ijantimicag.2015.07.020","article-title":"Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study","volume":"46","author":"Lee","year":"2015","journal-title":"International Journal of Antimicrobial Agents"},{"key":"2023020110333832100_ciac268-B86","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12879-016-1770-1","article-title":"Cefmetazole for bacteremia caused by ESBL-producing Enterobacteriaceae comparing with carbapenems","volume":"16","author":"Fukuchi","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2023020110333832100_ciac268-B87","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10096-019-03701-0","article-title":"Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase-producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis","volume":"39","author":"Senard","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B88","volume-title":"Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE): November 2015 update - CRE toolkit","author":"Centers for Disease Control and Prevention.","year":"2015"},{"key":"2023020110333832100_ciac268-B89","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/jac\/dkaa447","article-title":"IS26-mediated amplification of blaOXA-1 and blaCTX-M-15 with concurrent outer membrane porin disruption associated with de novo carbapenem resistance in a recurrent bacteraemia cohort","volume":"76","author":"Shropshire","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B90","doi-asserted-by":"crossref","first-page":"e0110521","DOI":"10.1128\/AAC.01105-21","article-title":"Detection and characterization of targeted carbapenem-resistant healthcare-associated threats: findings from the antibiotic resistance laboratory network, 2017 to 2019","volume":"65","author":"Sabour","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B91","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1473-3099(19)30755-8","article-title":"Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study","volume":"20","author":"van Duin","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2023020110333832100_ciac268-B92","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/cid\/ciw398","article-title":"High rates of nonsusceptibility to ceftazidime-avibactam and identification of New Delhi metallo-\u03b2-lactamase production in Enterobacteriaceae bloodstream infections at a major cancer center","volume":"63","author":"Aitken","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B93","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.diagmicrobio.2018.10.004","article-title":"Diversity of resistance mechanisms in carbapenem-resistant Enterobacteriaceae at a health care system in Northern California, from 2013 to 2016","volume":"93","author":"Senchyna","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B94","doi-asserted-by":"crossref","first-page":"e01140-18","DOI":"10.1128\/JCM.01140-18","article-title":"Phenotypic detection of carbapenemase-producing organisms from clinical isolates","volume":"56","author":"Tamma","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2023020110333832100_ciac268-B95","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/cid\/ciw741","article-title":"Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B96","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1128\/JCM.00267-10","article-title":"Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods","volume":"48","author":"Bulik","year":"2010","journal-title":"J Clin Microbiol"},{"key":"2023020110333832100_ciac268-B97","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12941-016-0155-z","article-title":"In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates","volume":"15","author":"Sutherland","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2023020110333832100_ciac268-B98","doi-asserted-by":"crossref","first-page":"e00313-18","DOI":"10.1128\/AAC.00313-18","article-title":"In vitro activity of plazomicin against gram-negative and gram-positive isolates collected from U.S. hospitals and comparative activities of aminoglycosides against carbapenem-resistant Enterobacteriaceae and isolates carrying carbapenemase genes","volume":"62","author":"Castanheira","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B99","doi-asserted-by":"crossref","first-page":"e02418-19","DOI":"10.1128\/AAC.02418-19","article-title":"Activity of plazomicin tested against Enterobacterales isolates collected from U.S. hospitals in 2016\u20132017: effect of different breakpoint criteria on susceptibility rates among aminoglycosides","volume":"64","author":"Castanheira","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B100","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B101","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2023020110333832100_ciac268-B102","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"2023020110333832100_ciac268-B103","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2023020110333832100_ciac268-B104","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections","volume":"72","author":"Sims","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B105","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2023020110333832100_ciac268-B106","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jinf.2019.06.011","article-title":"Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: dose is critical","volume":"79","author":"Sorli","year":"2019","journal-title":"J Infect"},{"key":"2023020110333832100_ciac268-B107","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/cid\/cit334","article-title":"Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens","volume":"57","author":"Sandri","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B108","doi-asserted-by":"crossref","first-page":"27","DOI":"10.21105\/joss.00027","article-title":"sourmash: a library for MinHash sketching of DNA","volume":"1","author":"Brown","year":"2016","journal-title":"J Open Source Softw"},{"key":"2023020110333832100_ciac268-B109","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1128\/AAC.03042-15","article-title":"In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014)","volume":"60","author":"de Jonge","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B110","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/jac\/dkz456","article-title":"In vitro activity of ceftazidime\/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015-17)","volume":"75","author":"Spiliopoulou","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B111","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1093\/jac\/dkab306","article-title":"Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime\/avibactam, meropenem\/vaborbactam and comparators against these isolates","volume":"76","author":"Castanheira","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B112","doi-asserted-by":"crossref","first-page":"e01951-19","DOI":"10.1128\/AAC.01951-19","article-title":"Meropenem-vaborbactam activity against carbapenem-resistant Enterobacterales isolates collected in U.S. hospitals during 2016 to 2018","volume":"64","author":"Castanheira","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B113","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijantimicag.2018.02.021","article-title":"In vitro activity of meropenem\/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem\/vaborbactam surveillance programme","volume":"52","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2023020110333832100_ciac268-B114","doi-asserted-by":"crossref","first-page":"e02408-19","DOI":"10.1128\/AAC.02408-19","article-title":"Activity of imipenem-relebactam against carbapenem-resistant Escherichia coli isolates from the United States in relation to clonal background, resistance genes, coresistance, and region","volume":"64","author":"Johnston","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B115","doi-asserted-by":"crossref","first-page":"e0228820","DOI":"10.1128\/AAC.02288-20","article-title":"Imipenem-relebactam susceptibility and genotypic characteristics of carbapenem-resistant Enterobacterales (CRE) identified during population-based surveillance","volume":"65","author":"Horwich-Scholefield","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B116","doi-asserted-by":"crossref","first-page":"106011","DOI":"10.1016\/j.ijantimicag.2020.106011","article-title":"Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and \u03b2-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values","volume":"56","author":"Castanheira","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2023020110333832100_ciac268-B117","doi-asserted-by":"crossref","first-page":"e00642-17","DOI":"10.1128\/AAC.00642-17","article-title":"Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae","volume":"61","author":"Haidar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B118","doi-asserted-by":"crossref","first-page":"e00672-19","DOI":"10.1128\/AAC.00672-19","article-title":"Activity of imipenem-relebactam and comparator agents against genetically characterized isolates of carbapenem-resistant Enterobacteriaceae","volume":"63","author":"Canver","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B119","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s10096-019-03517-y","article-title":"In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015\u20132016","volume":"38","author":"Galani","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B120","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1128\/AAC.02166-13","article-title":"Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems","volume":"58","author":"Daikos","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B121","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jac\/dkp139","article-title":"Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution","volume":"64","author":"Roberts","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B122","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/0091270003257225","article-title":"Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem","volume":"43","author":"Kuti","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"2023020110333832100_ciac268-B123","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/0091270006291035","article-title":"Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients","volume":"46","author":"Li","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"2023020110333832100_ciac268-B124","doi-asserted-by":"crossref","first-page":"e00883-17","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B125","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B126","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"2023020110333832100_ciac268-B127","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B128","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jac\/dkaa503","article-title":"Ceftazidime\/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study","volume":"76","author":"Karaiskos","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2021.05.079","article-title":"Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia","volume":"109","author":"Hakeam","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2023020110333832100_ciac268-B130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","article-title":"Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients","volume":"59","author":"Cast\u00f3n","year":"2017","journal-title":"Int J Infect Dis"},{"key":"2023020110333832100_ciac268-B131","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1186\/s12879-019-4409-1","article-title":"Efficacy of ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"19","author":"Alraddadi","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2023020110333832100_ciac268-B132","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B133","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-beta-lactamase-producing isolates (SIDERO-WT-2014 Study)","volume":"53","author":"Kazmierczak","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2023020110333832100_ciac268-B134","doi-asserted-by":"crossref","first-page":"e00397-20","DOI":"10.1128\/AAC.00397-20","article-title":"Metallo-\u03b2-lactamases: structure, function, epidemiology, treatment options, and the development pipeline","volume":"64","author":"Boyd","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B135","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/jpids\/piz002","article-title":"Defining the role of novel \u03b2-lactam agents that target carbapenem-resistant gram-negative organisms","volume":"8","author":"Tamma","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2023020110333832100_ciac268-B136","doi-asserted-by":"crossref","first-page":"ofaa051","DOI":"10.1093\/ofid\/ofaa051","article-title":"Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections","volume":"7","author":"Alosaimy","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023020110333832100_ciac268-B137","doi-asserted-by":"crossref","first-page":"e02313-19","DOI":"10.1128\/AAC.02313-19","article-title":"Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"64","author":"Ackley","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B138","doi-asserted-by":"crossref","first-page":"ftz040","DOI":"10.1093\/femspd\/ftz040","article-title":"Imipenem\/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical center","volume":"77","author":"Kulengowski","year":"2019","journal-title":"Pathog Dis"},{"key":"2023020110333832100_ciac268-B139","doi-asserted-by":"crossref","first-page":"115418","DOI":"10.1016\/j.diagmicrobio.2021.115418","article-title":"In vitro activity of imipenem-relebactam against various resistance phenotypes\/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016\u20132019","volume":"101","author":"Walkty","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B140","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jmii.2021.02.001","article-title":"Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan","volume":"55","author":"Yang","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"2023020110333832100_ciac268-B141","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1099\/jmm.0.001142","article-title":"In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples \u2013 SMART Surveillance Europe 2015\u20132017","volume":"69","author":"Lob","year":"2020","journal-title":"J Med Microbiol"},{"key":"2023020110333832100_ciac268-B142","doi-asserted-by":"crossref","first-page":"e00174-18","DOI":"10.1128\/AAC.00174-18","article-title":"Relebactam is a potent inhibitor of the KPC-2 beta-lactamase and restores imipenem susceptibility in KPC-producing Enterobacteriaceae","volume":"62","author":"Papp-Wallace","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B143","doi-asserted-by":"crossref","first-page":"e0217120","DOI":"10.1128\/AAC.02171-20","article-title":"New perspectives on antimicrobial agents: cefiderocol","volume":"65","author":"McCreary","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B144","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/jac\/dkx496","article-title":"Clinical outcomes after combination treatment with ceftazidime\/avibactam and aztreonam for NDM-1\/OXA-48\/CTX-M-15-producing Klebsiella pneumoniae infection","volume":"73","author":"Shaw","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B145","doi-asserted-by":"crossref","first-page":"e02463-18","DOI":"10.1128\/AAC.02463-18","article-title":"Successful treatment of bacteremia due to NDM-1-producing Morganella morganii with aztreonam and ceftazidime-avibactam combination in a pediatric patient with hematologic malignancy","volume":"63","author":"Hobson","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B146","doi-asserted-by":"crossref","first-page":"e01426-19","DOI":"10.1128\/AAC.01426-19","article-title":"Searching for the optimal treatment for metallo- and serine-\u03b2-lactamase producing Enterobacteriaceae: aztreonam in combination with ceftazidime-avibactam or meropenem-vaborbactam","volume":"63","author":"Biagi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B147","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/jac\/dkz495","article-title":"Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing Klebsiella pneumoniae using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime\/avibactam","volume":"75","author":"Sieswerda","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B148","doi-asserted-by":"crossref","first-page":"105842","DOI":"10.1016\/j.ijantimicag.2019.10.023","article-title":"Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime\/avibactam combined with aztreonam in solid organ transplant recipients: report of two cases","volume":"55","author":"Benchetrit","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2023020110333832100_ciac268-B149","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-\u03b2-lactamase\u2013producing Enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B150","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1093\/jac\/dkaa197","article-title":"Determining the optimal dosing of a novel combination regimen of ceftazidime\/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model","volume":"75","author":"Lodise","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B151","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s10096-017-3063-z","article-title":"Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant gram-negative pathogens","volume":"36","author":"Dobias","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B152","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ijantimicag.2018.11.015","article-title":"Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam","volume":"53","author":"De la Calle","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2023020110333832100_ciac268-B153","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1128\/AAC.01165-15","article-title":"First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate","volume":"59","author":"Humphries","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B154","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/jac\/dkv094","article-title":"Activity of ceftazidime\/avibactam against isogenic strains of Escherichia coli containing KPC and SHV beta-lactamases with single amino acid substitutions in the Omega-loop","volume":"70","author":"Winkler","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B155","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1128\/AAC.00678-15","article-title":"In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase","volume":"59","author":"Livermore","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B156","doi-asserted-by":"crossref","first-page":"e02097-16","DOI":"10.1128\/AAC.02097-16","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B157","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B158","doi-asserted-by":"crossref","first-page":"e00451-17","DOI":"10.1128\/AAC.00451-17","article-title":"Impaired inhibition by avibactam and resistance to the ceftazidime-avibactam combination due to the D179Y substitution in the KPC-2 \u03b2-lactamase","volume":"61","author":"Compain","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B159","doi-asserted-by":"crossref","first-page":"e02101-17","DOI":"10.1128\/AAC.02101-17","article-title":"Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates","volume":"62","author":"Giddins","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B160","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1093\/jac\/dkz330","article-title":"Emergence of ceftazidime\/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo","volume":"74","author":"G\u00f6ttig","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B161","doi-asserted-by":"crossref","first-page":"e00408-18","DOI":"10.1128\/mSphere.00408-18","article-title":"Analyses of a ceftazidime-avibactam-resistant Citrobacter freundii isolate carrying blaKPC-2 reveals a heterogenous population and reversible genotype","volume":"3","author":"Castanheira","year":"2018","journal-title":"mSphere"},{"key":"2023020110333832100_ciac268-B162","doi-asserted-by":"crossref","first-page":"e02048-18","DOI":"10.1128\/AAC.02048-18","article-title":"Effects of KPC variant and porin genotype on the in vitro activity of meropenem-vaborbactam against carbapenem-resistant Enterobacteriaceae","volume":"63","author":"Wilson","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B163","doi-asserted-by":"crossref","first-page":"124.e1","DOI":"10.1016\/j.cmi.2019.08.020","article-title":"Emergence of ceftazidime\/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China","volume":"26","author":"Zhang","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2023020110333832100_ciac268-B164","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.2147\/IDR.S207993","article-title":"Molecular and phenotypical characterization of two cases of antibiotic-driven ceftazidime-avibactam resistance in blaKPC-3-harboring Klebsiella pneumoniae","volume":"12","author":"Venditti","year":"2019","journal-title":"Infect Drug Resist"},{"key":"2023020110333832100_ciac268-B165","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jgar.2019.11.007","article-title":"Use of carbapenems in the combined treatment of emerging ceftazidime\/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: report of a case and review of the literature","volume":"22","author":"Cano","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2023020110333832100_ciac268-B166","doi-asserted-by":"crossref","first-page":"516.e1","DOI":"10.1016\/j.cmi.2019.11.011","article-title":"Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime\/avibactam: epidemiology and genomic characterization","volume":"26","author":"Gaibani","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2023020110333832100_ciac268-B167","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/jac\/dkz026","article-title":"Ceftazidime\/avibactam resistance associated with L169P mutation in the omega loop of KPC-2","volume":"74","author":"Hemarajata","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B168","doi-asserted-by":"crossref","first-page":"1900256","DOI":"10.2807\/1560-7917.ES.2019.24.19.1900256","article-title":"Emergence of ceftazidime-avibactam-resistant Klebsiella pneumoniae during treatment, Finland, December 2018","volume":"24","author":"R\u00e4is\u00e4nen","year":"2019","journal-title":"Euro Surveill"},{"key":"2023020110333832100_ciac268-B169","doi-asserted-by":"crossref","first-page":"e00389-17","DOI":"10.1128\/AAC.00389-17","article-title":"Unusual Escherichia coli PBP3 insertion sequence identified from a collection of carbapenem-resistant Enterobacteriaceae tested in vitro with a combination of ceftazidime-, ceftaroline-, or aztreonam-avibactam","volume":"61","author":"Zhang","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B170","doi-asserted-by":"crossref","first-page":"e01443-17","DOI":"10.1128\/AAC.01443-17","article-title":"Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae","volume":"61","author":"Lomovskaya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B171","doi-asserted-by":"crossref","first-page":"e01694-17","DOI":"10.1128\/AAC.01694-17","article-title":"Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae","volume":"61","author":"Sun","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B172","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1128\/AAC.00843-15","article-title":"Activity of meropenem combined with RPX7009, a novel \u03b2-lactamase inhibitor, against gram-negative clinical isolates in New York city","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B173","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1093\/jac\/dky251","article-title":"In vitro activity of meropenem combined with vaborbactam against KPC-producing Enterobacteriaceae in China","volume":"73","author":"Zhou","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B174","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1128\/AAC.00711-16","article-title":"Effect of the \u03b2-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae","volume":"60","author":"Castanheira","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B175","doi-asserted-by":"crossref","first-page":"e01659-18","DOI":"10.1128\/AAC.01659-18","article-title":"Pharmacokinetics\/pharmacodynamics of vaborbactam, a novel beta-lactamase inhibitor, in combination with meropenem","volume":"63","author":"Griffith","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B176","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/cid\/ciz1131","article-title":"Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"71","author":"Shields","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B177","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1128\/AAC.00830-15","article-title":"Activity of imipenem with relebactam against gram-negative pathogens from New York city","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B178","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1089\/mdr.2018.0065","article-title":"Effect of porins and blaKPC expression on activity of imipenem with relebactam in Klebsiella pneumoniae: can antibiotic combinations overcome resistance?","volume":"24","author":"Balabanian","year":"2018","journal-title":"Microb Drug Resist"},{"key":"2023020110333832100_ciac268-B179","doi-asserted-by":"crossref","first-page":"S251","DOI":"10.1093\/ofid\/ofy210.703","article-title":"696. Mechanism of cefiderocol high MIC mutants obtained in non-clinical FoR studies","volume":"5","author":"Ito","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2023020110333832100_ciac268-B180","article-title":"Resistance acquisition studies of cefiderocol by serial passage and in vitro pharmacodynamic model under human simulated exposure","author":"Kohira"},{"key":"2023020110333832100_ciac268-B181","article-title":"Frequency of resistance acquisition and resistance mechanisms to cefiderocol","author":"Kohira"},{"key":"2023020110333832100_ciac268-B182","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/mdr.2021.0095","article-title":"Defining baseline mechanisms of cefiderocol resistance in the Enterobacterales","volume":"28","author":"Simner","year":"2022","journal-title":"Microb Drug Resist"},{"key":"2023020110333832100_ciac268-B183","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/cid\/ciaa355","article-title":"Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in Enterobacter cloacae complex following exposure to cefepime","volume":"71","author":"Shields","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B184","doi-asserted-by":"crossref","first-page":"e00198","DOI":"10.1128\/AAC.00198-20","article-title":"Structural basis of reduced susceptibility to ceftazidime-avibactam and cefiderocol in Enterobacter cloacae due to AmpC R2 loop deletion","volume":"64","author":"Kawai","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B185","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/cid\/ciab888","article-title":"Progressive development of cefiderocol resistance in Escherichia coli during therapy is associated with increased blaNDM-5 copy number and gene expression","volume":"75","author":"Simner","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B186","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.idc.2020.05.001","article-title":"Resistance to novel \u03b2-lactam-\u03b2-lactamase inhibitor combinations: the","volume":"34","author":"Papp-Wallace","year":"2020","journal-title":"Infect Dis Clin North Am"},{"key":"2023020110333832100_ciac268-B187","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41579-019-0159-8","article-title":"Interplay between \u03b2-lactamases and new \u03b2-lactamase inhibitors","volume":"17","author":"Bush","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"2023020110333832100_ciac268-B188","doi-asserted-by":"crossref","first-page":"e02497-17","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B189","doi-asserted-by":"crossref","first-page":"ofab371","DOI":"10.1093\/ofid\/ofab371","article-title":"Real-world, multicenter experience with meropenem-vaborbactam for gram-negative bacterial infections including carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa","volume":"8","author":"Alosaimy","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023020110333832100_ciac268-B190","doi-asserted-by":"crossref","first-page":"e00797-20","DOI":"10.1128\/AAC.00797-20","article-title":"Activity of cefiderocol, ceftazidime-avibactam, and eravacycline against carbapenem-resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, coresistance, and region","volume":"64","author":"Johnston","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B191","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/138920009787048356","article-title":"Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline","volume":"10","author":"Falagas","year":"2009","journal-title":"Curr Drug Metab"},{"key":"2023020110333832100_ciac268-B192","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"2023020110333832100_ciac268-B193","doi-asserted-by":"crossref","first-page":"ii25","DOI":"10.1093\/jac\/dkt142","article-title":"Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies","volume":"68","author":"Eckmann","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B194","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1086\/431676","article-title":"The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data","volume":"41","author":"Babinchak","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B195","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s12879-019-4093-1","article-title":"In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China","volume":"19","author":"Zhao","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2023020110333832100_ciac268-B196","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/jac\/dkr242","article-title":"Efficacy and safety of tigecycline: a systematic review and meta-analysis","volume":"66","author":"Yahav","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B197","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s12325-020-01235-y","article-title":"Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis","volume":"37","author":"Zha","year":"2020","journal-title":"Adv Ther"},{"key":"2023020110333832100_ciac268-B198","doi-asserted-by":"crossref","first-page":"e12467","DOI":"10.1097\/MD.0000000000012467","article-title":"Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens","volume":"97","author":"Chen","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2023020110333832100_ciac268-B199","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/cc13858","article-title":"High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria","volume":"18","author":"De Pascale","year":"2014","journal-title":"Crit Care"},{"key":"2023020110333832100_ciac268-B200","doi-asserted-by":"crossref","first-page":"e3126","DOI":"10.1097\/MD.0000000000003126","article-title":"Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis","volume":"95","author":"Ni","year":"2016","journal-title":"Medicine (Baltimore"},{"key":"2023020110333832100_ciac268-B201","doi-asserted-by":"crossref","first-page":"e01699-19","DOI":"10.1128\/AAC.01699-19","article-title":"In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B202","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B203","doi-asserted-by":"crossref","first-page":"ofaa071","DOI":"10.1093\/ofid\/ofaa071","article-title":"Early experience with eravacycline for complicated infections","volume":"7","author":"Alosaimy","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023020110333832100_ciac268-B204","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1093\/ofid\/ofx163.221","article-title":"Minocycline in the treatment of carbapenem-resistant Klebsiella pneumoniae","volume":"4","author":"Khatri","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2023020110333832100_ciac268-B205","doi-asserted-by":"crossref","first-page":"S388","DOI":"10.1093\/cid\/ciu594","article-title":"Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center","volume":"59","author":"Pogue","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B206","doi-asserted-by":"crossref","first-page":"e02327-17","DOI":"10.1128\/AAC.02327-17","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe as part of the 2016 SENTRY antimicrobial surveillance program","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B207","doi-asserted-by":"crossref","first-page":"e02488-19","DOI":"10.1128\/AAC.02488-19","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: report from the SENTRY antimicrobial surveillance program, 2016 to 2018","volume":"64","author":"Pfaller","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B208","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s10096-020-03877-w","article-title":"In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017\u20132018","volume":"39","author":"Dong","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B209","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2023020110333832100_ciac268-B210","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B211","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2023020110333832100_ciac268-B212","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"2023020110333832100_ciac268-B213","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/138161213804070311","article-title":"Mechanisms of beta-lactam resistance among Pseudomonas aeruginosa","volume":"19","author":"Wolter","year":"2013","journal-title":"Curr Pharm Des"},{"key":"2023020110333832100_ciac268-B214","doi-asserted-by":"crossref","first-page":"e00472-17","DOI":"10.1128\/AAC.00472-17","article-title":"In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015","volume":"61","author":"Karlowsky","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B215","doi-asserted-by":"crossref","first-page":"e02569-17","DOI":"10.1128\/AAC.02569-17","article-title":"In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Asia-Pacific countries: results from the INFORM global surveillance program, 2012 to 2015","volume":"62","author":"Karlowsky","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B216","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/14787210.2017.1268918","article-title":"The epidemiology of carbapenemases in Latin America and the Caribbean","volume":"15","author":"Escandon-Vargas","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2023020110333832100_ciac268-B217","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/antibiotics9040153","article-title":"Carbapenem-resistant but cephalosporin-susceptible Pseudomonas aeruginosa in urinary tract infections: opportunity for colistin sparing","volume":"9","author":"Gajdacs","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2023020110333832100_ciac268-B218","doi-asserted-by":"crossref","first-page":"e0120421","DOI":"10.1128\/AAC.01204-21","article-title":"Elevated MICs of susceptible anti-pseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant Pseudomonas aeruginosa: implications for dose optimization","author":"Gill","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B219","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1556\/030.66.2019.036","article-title":"Characterization of carbapenem-resistant but cephalosporin-susceptible Pseudomonas aeruginosa","volume":"66","author":"Khalili","year":"2019","journal-title":"Acta Microbiol Immunol Hung"},{"key":"2023020110333832100_ciac268-B220","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bjid.2016.10.008","article-title":"Carbapenem-resistant and cephalosporin-susceptible: a worrisome phenotype among Pseudomonas aeruginosa clinical isolates in Brazil","volume":"21","author":"Campana","year":"2017","journal-title":"Braz J Infect Dis"},{"key":"2023020110333832100_ciac268-B221","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.diagmicrobio.2013.11.014","article-title":"Mechanisms of carbapenem resistance in cephalosporin-susceptible Pseudomonas aeruginosa in China","volume":"78","author":"Zeng","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B222","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/microorganisms6010009","article-title":"Therapeutic management of Pseudomonas aeruginosa bloodstream infection non-susceptible to carbapenems but susceptible to","volume":"6","author":"Zaidenstein","year":"2018","journal-title":"Microorganisms"},{"key":"2023020110333832100_ciac268-B223","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2147\/IDR.S174876","article-title":"Carbapenem-resistant and cephalosporin-susceptible Pseudomonas aeruginosa: a notable phenotype in patients with bacteremia","volume":"11","author":"Li","year":"2018","journal-title":"Infect Drug Resist"},{"key":"2023020110333832100_ciac268-B224","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"2023020110333832100_ciac268-B225","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1128\/AAC.02744-13","article-title":"In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011\u20132012","volume":"58","author":"Walkty","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B226","doi-asserted-by":"crossref","first-page":"e01551-18","DOI":"10.1128\/AAC.01551-18","article-title":"Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant Klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient","volume":"63","author":"Athans","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B227","doi-asserted-by":"crossref","first-page":"e02125-17","DOI":"10.1128\/AAC.02125-17","article-title":"Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015","volume":"62","author":"Castanheira","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B228","doi-asserted-by":"crossref","first-page":"e01045-17","DOI":"10.1128\/AAC.01045-17","article-title":"Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. Medical Centers, 2013 to 2016","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B229","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.diagmicrobio.2018.11.021","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015\u20132017) isolates from hospitalized patients with pneumonia in US medical centers","volume":"94","author":"Carvalhaes","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B230","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.diagmicrobio.2018.05.011","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013\u20132015) as part of the program to assess ceftolozane-tazobactam susceptibility (PACTS) surveillance program","volume":"92","author":"Shortridge","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B231","doi-asserted-by":"crossref","first-page":"e02165-19","DOI":"10.1128\/AAC.02165-19","article-title":"Activity of imipenem-relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic beta-lactam-resistant mutants","volume":"64","author":"Fraile-Ribot","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B232","doi-asserted-by":"crossref","first-page":"114833","DOI":"10.1016\/j.diagmicrobio.2019.05.005","article-title":"Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017\u20132018)","volume":"96","author":"Sader","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B233","doi-asserted-by":"crossref","first-page":"e01587-18","DOI":"10.1128\/AAC.01587-18","article-title":"Antimicrobial susceptibility of Pseudomonas aeruginosa to ceftazidime-avibactam, ceftolozane-tazobactam, piperacillin-tazobactam, and meropenem stratified by U.S. census divisions: results from the 2017 INFORM program","volume":"62","author":"Sader","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B234","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1093\/jac\/dky227","article-title":"Murepavadin activity tested against contemporary (2016\u201317) clinical isolates of XDR Pseudomonas aeruginosa","volume":"73","author":"Sader","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B235","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/mdr.2017.0266","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2013\u20132016) as part of the surveillance program: program to sssess ceftolozane-tazobactam susceptibility","volume":"24","author":"Shortridge","year":"2018","journal-title":"Microb Drug Resist"},{"key":"2023020110333832100_ciac268-B236","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijantimicag.2017.09.016","article-title":"Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an antimicrobial surveillance programme (2013\u20132015)","volume":"51","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2023020110333832100_ciac268-B237","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bjid.2017.06.008","article-title":"Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013\u20132015)","volume":"21","author":"Pfaller","year":"2017","journal-title":"Braz J Infect Dis"},{"key":"2023020110333832100_ciac268-B238","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jgar.2017.05.025","article-title":"Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: report from an antimicrobial surveillance program (2013\u20132015)","volume":"10","author":"Pfaller","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"key":"2023020110333832100_ciac268-B239","doi-asserted-by":"crossref","first-page":"e00465-17","DOI":"10.1128\/AAC.00465-17","article-title":"Ceftolozane-tazobactam activity against Pseudomonas aeruginosa clinical isolates from U.S. hospitals: report from the PACTS antimicrobial surveillance program, 2012 to 2015","volume":"61","author":"Shortridge","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B240","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jac\/dkx009","article-title":"Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012\u201315)","volume":"72","author":"Pfaller","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B241","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1093\/jac\/dky279","article-title":"Frequency and antimicrobial susceptibility of gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015\u201317)","volume":"73","author":"Sader","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B242","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1089\/mdr.2020.0217","article-title":"Antimicrobial activity of ceftazidime-avibactam, ceftolozane-tazobactam and comparators tested against Pseudomonas aeruginosa and Klebsiella pneumoniae isolates from United States Medical Centers in 2016\u20132018","volume":"27","author":"Sader","year":"2021","journal-title":"Microb Drug Resist"},{"key":"2023020110333832100_ciac268-B243","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1128\/AAC.02429-13","article-title":"Antimicrobial activity of ceftazidime-avibactam against gram-negative organisms collected from U.S. medical centers in 2012","volume":"58","author":"Sader","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B244","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1128\/AAC.05024-14","article-title":"Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013","volume":"59","author":"Sader","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B245","doi-asserted-by":"crossref","first-page":"e02252-16","DOI":"10.1128\/AAC.02252-16","article-title":"Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012 to 2015) of the international network for optimal resistance monitoring program in the United States","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B246","doi-asserted-by":"crossref","first-page":"e02083-16","DOI":"10.1128\/AAC.02083-16","article-title":"Antimicrobial activity of ceftazidime-avibactam against gram-negative bacteria isolated from patients hospitalized with pneumonia in U.S. Medical Centers, 2011 to 2015","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B247","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.diagmicrobio.2016.11.019","article-title":"Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013\u20132014)","volume":"87","author":"Sader","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B248","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1128\/AAC.00405-16","article-title":"Antimicrobial activities of ceftazidime-avibactam and comparator agents against gram-negative organisms isolated from patients with urinary tract infections in U.S. Medical Centers, 2012 to 2014","volume":"60","author":"Sader","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B249","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1089\/sur.2016.036","article-title":"Ceftazidime-avibactam activity against aerobic gram negative organisms isolated from intra-abdominal infections in United States hospitals, 2012\u20132014","volume":"17","author":"Sader","year":"2016","journal-title":"Surg Infect (Larchmt)"},{"key":"2023020110333832100_ciac268-B250","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1128\/AAC.03056-15","article-title":"In vitro activity of ceftazidime-avibactam against contemporary Pseudomonas aeruginosa isolates from U.S. Medical centers by census region, 2014","volume":"60","author":"Huband","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B251","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.diagmicrobio.2015.06.008","article-title":"Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011\u20132014)","volume":"83","author":"Sader","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B252","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijantimicag.2015.02.022","article-title":"Ceftazidime\/avibactam tested against gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia","volume":"46","author":"Sader","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2023020110333832100_ciac268-B253","doi-asserted-by":"crossref","first-page":"ofab320","DOI":"10.1093\/ofid\/ofab320","article-title":"Ceftolozane\/tazobactam and imipenem\/relebactam cross-susceptibility among clinical isolates of Pseudomonas aeruginosa from patients with respiratory tract infections in ICU and non-ICU wards-SMART United States 2017\u20132019","volume":"8","author":"Lob","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023020110333832100_ciac268-B254","doi-asserted-by":"crossref","first-page":"115421","DOI":"10.1016\/j.diagmicrobio.2021.115421","article-title":"Activity of imipenem\/relebactam and comparators against gram-negative pathogens from patients with bloodstream infections in the United States and Canada - SMART 2018\u20132019","volume":"100","author":"Lob","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B255","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1093\/jac\/dkab141","article-title":"In vitro activity of imipenem\/relebactam, meropenem\/vaborbactam, ceftazidime\/avibactam, cefepime\/zidebactam and other novel antibiotics against imipenem-non-susceptible gram-negative bacilli from Taiwan","volume":"76","author":"Kuo","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B256","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/jpids\/piaa056","article-title":"In vitro activity of imipenem\/relebactam against gram-negative bacilli from pediatric patients-study for monitoring antimicrobial resistance trends (SMART) global surveillance program 2015\u20132017","volume":"10","author":"Karlowsky","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2023020110333832100_ciac268-B257","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/ciaa381","article-title":"In vitro activity of imipenem\/relebactam and ceftolozane\/tazobactam against clinical isolates of gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes - SMART United States 2015\u20132017","volume":"72","author":"Karlowsky","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B258","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.diagmicrobio.2017.02.018","article-title":"In vitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015: results from the SMART global surveillance program","volume":"88","author":"Lob","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B259","doi-asserted-by":"crossref","first-page":"105841","DOI":"10.1016\/j.ijantimicag.2019.10.022","article-title":"In-vitro activity of imipenem\/relebactam and key beta-lactam agents against gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015\u20132017","volume":"55","author":"Karlowsky","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2023020110333832100_ciac268-B260","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jgar.2019.10.028","article-title":"In vitro activity of imipenem\/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015\u20132017","volume":"21","author":"Karlowsky","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2023020110333832100_ciac268-B261","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.diagmicrobio.2019.05.001","article-title":"Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015\u20132017","volume":"95","author":"Karlowsky","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B262","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1093\/jac\/dkz191","article-title":"Activity of imipenem\/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015\u201317","volume":"74","author":"Lob","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B263","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jgar.2018.07.012","article-title":"Activity of imipenem\/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015\u20132016","volume":"15","author":"Karlowsky","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"2023020110333832100_ciac268-B264","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jgar.2018.05.017","article-title":"Activity of imipenem\/relebactam against gram-negative bacilli from global ICU and non-ICU wards: SMART 2015\u20132016","volume":"15","author":"Lob","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"2023020110333832100_ciac268-B265","doi-asserted-by":"crossref","first-page":"e00169-18","DOI":"10.1128\/AAC.00169-18","article-title":"In vitro activity of imipenem-relebactam against clinical isolates of gram-negative bacilli isolated in hospital laboratories in the United States as part of the SMART 2016 program","volume":"62","author":"Karlowsky","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B266","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/jac\/dky107","article-title":"In vitro activity of imipenem\/relebactam against gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme","volume":"73","author":"Karlowsky","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B267","doi-asserted-by":"crossref","first-page":"e02209-16","DOI":"10.1128\/AAC.02209-16","article-title":"In vitro activity of imipenem-relebactam against gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (results from the SMART global surveillance program)","volume":"61","author":"Lob","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B268","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.2147\/IDR.S325520","article-title":"Susceptibility to imipenem\/relebactam of Pseudomonas aeruginosa and acinetobacter baumannii isolates from Chinese intra-abdominal, respiratory and urinary tract infections: SMART 2015 to 2018","volume":"14","author":"Zhang","year":"2021","journal-title":"Infect Drug Resist"},{"key":"2023020110333832100_ciac268-B269","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B270","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2023020110333832100_ciac268-B271","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2023020110333832100_ciac268-B272","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B273","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1128\/AAC.00049-14","article-title":"Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections","volume":"58","author":"Lucasti","year":"2014","journal-title":"Antimicrobial Agents & Chemotherapy"},{"key":"2023020110333832100_ciac268-B274","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1128\/AAC.00633-16","article-title":"Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection","volume":"60","author":"Lucasti","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B275","doi-asserted-by":"crossref","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI2 study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B276","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B277","doi-asserted-by":"crossref","first-page":"dlab126","DOI":"10.1093\/jacamr\/dlab126","article-title":"Antimicrobial activity of ceftazidime\/avibactam, ceftolozane\/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients","volume":"3","author":"Sader","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2023020110333832100_ciac268-B278","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2147\/IDR.S173804","article-title":"Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam","volume":"11","author":"Atkin","year":"2018","journal-title":"Infect Drug Resist"},{"key":"2023020110333832100_ciac268-B279","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1093\/jac\/dky204","article-title":"Clinical activity of ceftazidime\/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime\/avibactam Phase III clinical trial programme","volume":"73","author":"Stone","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B280","doi-asserted-by":"crossref","first-page":"e01454-17","DOI":"10.1128\/AAC.01454-17","article-title":"In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria","volume":"62","author":"Ito","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B281","doi-asserted-by":"crossref","first-page":"e01955-19","DOI":"10.1128\/AAC.01955-19","article-title":"Activity of cefiderocol and comparators against isolates from cancer patients","volume":"64","author":"Rolston","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B282","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1093\/jac\/dkx049","article-title":"Activity of cefiderocol (S-649266) against carbapenem-resistant gram-negative bacteria collected from inpatients in Greek hospitals","volume":"72","author":"Falagas","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B283","doi-asserted-by":"crossref","first-page":"115012","DOI":"10.1016\/j.diagmicrobio.2020.115012","article-title":"In vitro activity of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacilli isolated from patients in Canadian intensive care units","volume":"97","author":"Golden","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B284","doi-asserted-by":"crossref","first-page":"e01968-17","DOI":"10.1128\/AAC.01968-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B285","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijantimicag.2018.11.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015\u20132016: SIDERO-WT-2015","volume":"53","author":"Karlowsky","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2023020110333832100_ciac268-B286","doi-asserted-by":"crossref","first-page":"e00093-17","DOI":"10.1128\/AAC.00093-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 study)","volume":"61","author":"Hackel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B287","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2023020110333832100_ciac268-B288","first-page":"9095203","article-title":"In vivo resistance to ceftolozane\/tazobactam in Pseudomonas aeruginosa arising by AmpC- and non-AmpC-mediated pathways","volume":"2018","author":"Skoglund","year":"2018","journal-title":"Case Rep Infect Dis"},{"key":"2023020110333832100_ciac268-B289","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1128\/AAC.00825-15","article-title":"Mutations in beta-lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins","volume":"59","author":"Berrazeg","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B290","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jac\/dkx424","article-title":"Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa","volume":"73","author":"Fraile-Ribot","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B291","doi-asserted-by":"crossref","first-page":"e01183-17","DOI":"10.1128\/AAC.01183-17","article-title":"Emergence of ceftolozane-tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation","volume":"61","author":"MacVane","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B292","first-page":"269","article-title":"Mechanisms of high-level ceftolozane\/tazobactam resistance in Pseudomonas aeruginosa from a severely neutropenic patient and treatment success from synergy with tobramycin","volume":"74","author":"So","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B293","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ijantimicag.2019.02.022","article-title":"Phylogenetic analysis of resistance to ceftazidime\/avibactam, ceftolozane\/tazobactam and carbapenems in piperacillin\/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients","volume":"53","author":"Zamudio","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2023020110333832100_ciac268-B294","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B295","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s10096-018-3361-0","article-title":"Ceftolozane\/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands","volume":"37","author":"Diaz-Canestro","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B296","doi-asserted-by":"crossref","first-page":"e01637-19","DOI":"10.1128\/AAC.01637-19","article-title":"A 2.5-years within-patient evolution of a Pseudomonas aeruginosa with in vivo acquisition of ceftolozane-tazobactam and ceftazidime-avibactam resistance upon treatment","volume":"63","author":"Boulant","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B297","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1128\/AAC.03681-14","article-title":"Mutation-driven beta-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals","volume":"58","author":"Castanheira","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B298","doi-asserted-by":"crossref","first-page":"e00084-21","DOI":"10.1128\/AAC.00084-21","article-title":"In vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa following treatment-emergent resistance to ceftolozane-tazobactam","volume":"65","author":"Rubio","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B299","doi-asserted-by":"crossref","first-page":"e4599","DOI":"10.1093\/cid\/ciaa1306","article-title":"Modifiable risk factors for the emergence of ceftolozane-tazobactam resistance","volume":"73","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B300","doi-asserted-by":"crossref","first-page":"e01822-19","DOI":"10.1128\/mBio.01822-19","article-title":"Dynamic emergence of mismatch repair deficiency facilitates rapid evolution of ceftazidime-avibactam resistance in Pseudomonas aeruginosa acute infection","volume":"10","author":"Khil","year":"2019","journal-title":"mBio"},{"key":"2023020110333832100_ciac268-B301","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/jac\/dkv004","article-title":"Selection and molecular characterization of ceftazidime\/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC","volume":"70","author":"Lahiri","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B302","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1093\/jac\/dkaa206","article-title":"In vitro dynamics and mechanisms of resistance development to imipenem and imipenem\/relebactam in Pseudomonas aeruginosa","volume":"75","author":"Gomis-Font","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B303","doi-asserted-by":"crossref","first-page":"e4472","DOI":"10.1093\/cid\/ciaa1909","article-title":"Evolution of cefiderocol non-susceptibility in Pseudomonas aeruginosa in a patient without previous exposure to the antibiotic","volume":"73","author":"Streling","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B304","doi-asserted-by":"crossref","first-page":"ofab311","DOI":"10.1093\/ofid\/ofab311","article-title":"Cefiderocol activity against clinical Pseudomonas aeruginosa isolates exhibiting ceftolozane-tazobactam resistance","volume":"8","author":"Simner","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023020110333832100_ciac268-B305","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1586\/14787210.5.5.811","article-title":"Polymyxin B: similarities to and differences from colistin (polymyxin E)","volume":"5","author":"Kwa","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2023020110333832100_ciac268-B306","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/cid\/cit453","article-title":"Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center","volume":"57","author":"Akajagbor","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B307","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1128\/AAC.02476-13","article-title":"In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy","volume":"58","author":"Phe","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B308","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ijantimicag.2013.12.002","article-title":"Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium","volume":"43","author":"Tuon","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2023020110333832100_ciac268-B309","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1128\/AAC.02634-15","article-title":"Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B","volume":"60","author":"Rigatto","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B310","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.diagmicrobio.2009.07.018","article-title":"Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity","volume":"65","author":"Oliveira","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B311","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/ALN.0b013e31827515de","article-title":"Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii","volume":"117","author":"Lu","year":"2012","journal-title":"Anesthesiology"},{"key":"2023020110333832100_ciac268-B312","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1086\/432583","article-title":"Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa","volume":"41","author":"Kwa","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B313","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.rmed.2008.11.018","article-title":"Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series","volume":"103","author":"Falagas","year":"2009","journal-title":"Respir Med"},{"key":"2023020110333832100_ciac268-B314","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3349\/ymj.2014.55.1.118","article-title":"Inhaled colistin for treatment of pneumonia due to colistin-only-susceptible Acinetobacter baumannii","volume":"55","author":"Choi","year":"2014","journal-title":"Yonsei Med J"},{"key":"2023020110333832100_ciac268-B315","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jmii.2014.08.009","article-title":"Role of aerosolized colistin methanesulfonate therapy for extensively-drug-resistant Acinetobacter baumannii complex pneumonia and airway colonization","volume":"49","author":"Hsieh","year":"2016","journal-title":"J Microbiol Immunol Infect"},{"key":"2023020110333832100_ciac268-B316","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ppul.22750","article-title":"Colistin inhalation monotherapy for ventilator-associated pneumonia of Acinetobacter baumannii in prematurity","volume":"49","author":"Kang","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"2023020110333832100_ciac268-B317","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4103\/2319-4170.132879","article-title":"Influencing factors of successful eradication of multidrug-resistant Acinetobacter baumannii in the respiratory tract with aerosolized colistin","volume":"37","author":"Chen","year":"2014","journal-title":"Biomed J"},{"key":"2023020110333832100_ciac268-B318","doi-asserted-by":"crossref","first-page":"e12278","DOI":"10.1097\/MD.0000000000012278","article-title":"Treatment outcomes of patients with non-bacteremic pneumonia caused by extensively drug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolates: is there any benefit of adding tigecycline to aerosolized colistimethate sodium?","volume":"97","author":"Jean","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2023020110333832100_ciac268-B319","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1378\/chest.13-1018","article-title":"Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria","volume":"144","author":"Tumbarello","year":"2013","journal-title":"Chest"},{"key":"2023020110333832100_ciac268-B320","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1086\/657242","article-title":"Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study","volume":"51","author":"Kofteridis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B321","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1097\/CCM.0000000000001539","article-title":"The role of aerolized colistin in the treatment of hospital-acquired pneumonia: experience of multicenter from Turkey","volume":"44","author":"Korkmaz Ekren","year":"2016","journal-title":"Crit Care Med"},{"key":"2023020110333832100_ciac268-B322","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12941-016-0123-7","article-title":"Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by Acinetobacter baumannii?","volume":"15","author":"Demirdal","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2023020110333832100_ciac268-B323","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13613-016-0127-7","article-title":"Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial","volume":"6","author":"Abdellatif","year":"2016","journal-title":"Ann Intensive Care"},{"key":"2023020110333832100_ciac268-B324","doi-asserted-by":"crossref","first-page":"555","DOI":"10.21037\/jtd.2017.02.61","article-title":"Efficacy of nebulized colistin-based therapy without concurrent intravenous colistin for ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii","volume":"9","author":"Kim","year":"2017","journal-title":"J Thorac Dis"},{"key":"2023020110333832100_ciac268-B325","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.rmed.2007.10.011","article-title":"Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant gram-negative bacteria: a prospective study","volume":"102","author":"Michalopoulos","year":"2008","journal-title":"Respir Med"},{"key":"2023020110333832100_ciac268-B326","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s10156-012-0430-7","article-title":"Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment?","volume":"18","author":"Kalin","year":"2012","journal-title":"J Infect Chemother"},{"key":"2023020110333832100_ciac268-B327","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/1471-2334-11-317","article-title":"A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa","volume":"11","author":"Naesens","year":"2011","journal-title":"BMC Infect Dis"},{"key":"2023020110333832100_ciac268-B328","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1684-1182(10)60050-3","article-title":"Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan","volume":"43","author":"Lin","year":"2010","journal-title":"J Microbiol Immunol Infect"},{"key":"2023020110333832100_ciac268-B329","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2253-13-45","article-title":"Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: a retrospective study","volume":"13","author":"Doshi","year":"2013","journal-title":"BMC Anesthesiol"},{"key":"2023020110333832100_ciac268-B330","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/sur.2007.004","article-title":"Pseudomonas aeruginosa susceptible only to colistin in intensive care unit patients","volume":"9","author":"Mastoraki","year":"2008","journal-title":"Surg Infect (Larchmt)"},{"key":"2023020110333832100_ciac268-B331","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/ajhp\/62.1.39","article-title":"Use of colistin in the treatment of multiple-drug-resistant gram-negative infections","volume":"62","author":"Berlana","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"2023020110333832100_ciac268-B332","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1469-0691.2009.03040.x","article-title":"Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study","volume":"16","author":"Korbila","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"2023020110333832100_ciac268-B333","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/cc3020","article-title":"Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis","volume":"9","author":"Michalopoulos","year":"2005","journal-title":"Crit Care"},{"key":"2023020110333832100_ciac268-B334","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.burns.2009.07.010","article-title":"Use of colistin in treating multi-resistant gram-negative organisms in a specialised burns unit","volume":"36","author":"Ganapathy","year":"2010","journal-title":"Burns"},{"key":"2023020110333832100_ciac268-B335","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10096-006-0191-2","article-title":"Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria","volume":"25","author":"Falagas","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023020110333832100_ciac268-B336","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1469-0691.2011.03682.x","article-title":"Eradication of multidrug-resistant Acinetobacter baumannii from the respiratory tract with inhaled colistin methanesulfonate: a matched case-control study","volume":"18","author":"Kuo","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2023020110333832100_ciac268-B337","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jinf.2005.11.019","article-title":"Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii","volume":"53","author":"Motaouakkil","year":"2006","journal-title":"J Infect"},{"key":"2023020110333832100_ciac268-B338","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jcrc.2017.04.004","article-title":"Efficacy and toxicity of high-dose nebulized colistin for critically ill surgical patients with ventilator-associated pneumonia caused by multidrug-resistant Acinetobacter baumannii","volume":"40","author":"Jang","year":"2017","journal-title":"J Crit Care"},{"key":"2023020110333832100_ciac268-B339","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1093\/jac\/dkq360","article-title":"Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by gram-negative bacteria","volume":"65","author":"Rattanaumpawan","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2023020110333832100_ciac268-B340","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.chest.2016.11.026","article-title":"A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of gram-negative ventilator-associated pneumonia: IASIS trial","volume":"151","author":"Kollef","year":"2017","journal-title":"Chest"},{"key":"2023020110333832100_ciac268-B341","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1473-3099(19)30574-2","article-title":"Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial","volume":"20","author":"Niederman","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2023020110333832100_ciac268-B342","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1128\/AAC.03510-14","article-title":"Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients","volume":"58","author":"Boisson","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020110333832100_ciac268-B343","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1097\/ALN.0b013e3182755d7a","article-title":"Aerosolized antibiotics for ventilator-associated pneumonia: lessons from experimental studies","volume":"117","author":"Rouby","year":"2012","journal-title":"Anesthesiology"},{"key":"2023020110333832100_ciac268-B344","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1128\/CMR.00101-15","article-title":"Inhaled antibiotics for gram-negative respiratory infections","volume":"29","author":"Wenzler","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"2023020110333832100_ciac268-B345","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/antibiotics8010027","article-title":"A breath of fresh air in the fog of antimicrobial resistance: inhaled polymyxins for gram-negative pneumonia","volume":"8","author":"Biagi","year":"2019","journal-title":"Antibiotics (Basel)"},{"key":"2023020110333832100_ciac268-B346","doi-asserted-by":"crossref","first-page":"e61\u2013111","DOI":"10.1093\/cid\/ciw504","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023020110333832100_ciac268-B347","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2023020110333832100_ciac268-B348","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cmi.2017.04.011","article-title":"Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases","volume":"23","author":"Rello","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2023020110333832100_ciac268-B349","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3390\/ijms18051062","article-title":"Inhaled antibiotic therapy in chronic respiratory diseases","volume":"18","author":"Maselli","year":"2017","journal-title":"Int J Mol Sci"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac268\/44258251\/ciac268.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/2\/187\/49018000\/ciac268.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/2\/187\/49018000\/ciac268.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T17:00:18Z","timestamp":1675270818000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/2\/187\/6570801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":349,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,4,19]]},"published-print":{"date-parts":[[2022,8,25]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac268","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,15]]},"published":{"date-parts":[[2022,4,19]]}}}